MRKR · Marker Therapeutics, Inc.
AI read · Good for MRKR
The AI's read
The money can help Marker continue work on its lead treatment. MT-601 is still being tested, so the award does not show that it works or will reach patients.
Marker Therapeutics, Inc. says it got a $2.6 million grant from the FDA for its MT-601 cancer treatment.
Good for MRKR
Marker Therapeutics won a $2.6 million FDA grant to advance MT-601 for pancreatic cancer. The funding supports work on its lead treatment, though the treatment remains investigational.
Get alerts for MRKR
Follow Marker Therapeutics, Inc. (MRKR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRKRFree on the App Store and Google Play, or on the web.